Clinical Trial of Topical ABL01 Treatment of Onychomycosis

NCT ID: NCT03141840

Last Updated: 2019-02-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 69 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-14
• Study Completion Date: 2019-02-08

Brief Summary

This clinical trial seeks to investigate if an experimental medical device, ABL01, can be used to treat onychomycosis. In a 1-year trial the effectiveness of ABL01 will be tested against placebo in 70 study subjects with onychomycosis of the big toe nail. The endpoint of the trial is clinical improvement and cure at the 6 and 12 month time-point.

Detailed Description

The purpose of this clinical trial is to determine the safety and effectiveness of the medical device ABL01. The intended use of ABL01 is to reduce and treat onychomycosis, fungal nail infection. ABL01 is a solution intended to be topically administered weekly to infected nails. The trial is designed as a double blinded randomized placebo controlled clinical trial. The trial involves 70 study subjects, half of which will receive ABL01 and the other half placebo. The inclusion criteria for study subjects are adult men and women that present with distal lateral subungual onychomycosis (DSU) on the big toe nails. Furthermore, the extent of DSU should not involve more than half of the area of the nail.

The study subjects will themselves apply the study solution weekly to the treated nail. The trial will run for 6 months with a possible extension to maximum 12 months. There will be a total of 4 study visits at baseline, 3, 6 and 12 months to follow up the progress of the trial. The primary objective of the trial is to determine if ABL01 treatment are able to reduce and treat onychomycosis. Secondary objectives are to collect safety data, determine if the ABL01 are perceived as easy to use and assess long term effects of the treatment. The endpoint of the trial is reduction in clinical signs or complete cure of onychomycosis at the 6- or 12-month time-point.

Conditions

Onychomycosis of Toenail

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Experimental

Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.

Group Type: EXPERIMENTAL

ABL01

Intervention Type: DEVICE

Experimental medical device

Control

Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DEVICE

ABL01 lacking active component

Interventions

ABL01

Experimental medical device

Intervention Type: DEVICE

Placebo

ABL01 lacking active component

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Provision of written informed consent
• Men and women above age 18 weighing over 40 kg
• Present with distal lateral subungual onychomycosis of any of the big toe nails
• The onychomycosis should involve less than 50 % of the nail bed and may not have reached the cuticle

Exclusion Criteria

• Unable to come for study visits
• Known allergy to any of the components in ABL01
• Not willing to participate in the trial or not able to understand the content of the trial
• Present with proximal subungual onychomycosis or superficial onychomycosis.
• Present with distal lateral subungual onychomycosis of other nails than the big toe.
• More than 50 % of the nailbed affected by onychomycosis or the cuticles infected
• Known conditions (like psoriasis) that cause abnormal nail appearance
• Nail damage caused by trauma, pressure or other mechanical reasons
• Currently on immunosuppressive therapy
• Showing signs of poor peripheral blood circulation
• Used another topical antifungal treatment within 1 month of screening
• Used a systemic antifungal treatment within 3 months of screening
• Participated in any other clinical onychomycosis trial in the previous 3 months

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Abbell AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Irini Mouratidou-Kontorinis

Role: PRINCIPAL_INVESTIGATOR

Fotcompaniet Stockholm

Locations

Fotcompaniet Stockholm

Stockholm, , Sweden

Countries

Sweden

Other Identifiers

AB001

Identifier Type: -

Identifier Source: org_study_id